OrthoPediatrics Boosts Revenue Guidance on Strong Q2 Growth
Event summary
- Q2 2026 revenue hit $70.5M, up 15% YoY, with domestic and international growth of 14% and 22%, respectively.
- Trauma & Deformity revenue surged 26% YoY, while Scoliosis revenue declined 9% due to lower set sales.
- Adjusted EBITDA reached a record $6.8M, up from $4.1M in Q2 2025.
- Free cash flow usage improved by $10.8M (78%) YoY.
- Full-year revenue guidance raised to $265M–$269M, up from $263M–$267M.
The big picture
OrthoPediatrics' Q2 results highlight its ability to balance revenue growth with profitability improvements, a critical inflection point for the company. The strategic focus on Trauma & Deformity products and international expansion positions it well in the competitive pediatric orthopedics market. However, sustaining momentum in Scoliosis and maintaining operational efficiency will be key to meeting upgraded full-year guidance.
What we're watching
- Revenue Diversification
- Whether OrthoPediatrics can sustain Trauma & Deformity growth while recovering Scoliosis revenue.
- Cash Flow Improvement
- The pace at which free cash flow breakeven is achieved in 2026.
- Strategic Partnerships
- How the OSSIO distribution agreement impacts product innovation and market expansion.
Related topics